- Repurposing of medicines has potential to accelerate treatments to patients
- RNA is considered nearly impossible to target directly with small molecules
- Dovitinib, targets receptor tyrosine kinases (RTKs) and binds to a functional site in the oncogenic microRNA precursor, pre-miR-21, inhibiting its processing
- A RIBOTAC of Dovitinib shifted the selectivity to pre-miR-21 by 2500-fold
- Targeted degradation affected the progression of metastasis of breast cancer and Alport syndrome, a genetically defined disease of the kidney